Can Valeant Pharmaceuticals Intl Inc. Dig Itself out of its Financial Hole?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in danger of defaulting on its debt.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is facing a lot of problems right now, but the biggest one revolves around its balance sheet. The company has roughly US$31 billion of debt as of December 31, according to unaudited figures, nearly three times its market value.

In fact, Valeant is in severe danger of defaulting on this debt, which is part of the reason why its shares fell so far on Monday. We’ll take a closer look and examine what the company must do to dig itself out of this hole.

A delay in reporting

In its press release on Monday, Valeant claimed that it could not release audited financial statements due to the ongoing investigation of Philidor. But this delay poses a big problem for the company.

Valeant’s bond indentures required the company to file its 10K form (which must include audited financials) by March 16, and since that wasn’t done, a notice of default can now be submitted. In that case, Valeant will have 60 days to then submit its 10K, otherwise the company will have to default on its debt.

Likewise, Valeant’s credit agreement requires a 10K by the end of the month in order to avoid a notice of default. Then once a notice is given, Valeant would have 30 days to comply.

These deadlines may be too tight for the company. During the conference call, CEO Michael Pearson said that it is negotiating with lenders to extend these deadlines.

Other issues

If we are to believe Valeant, then it is just a coincidence that it failed to file its 10K at the same time that it lowered its guidance. For the more cynically minded, these two things have something to do with each other. To make us even more suspicious, Valeant did not release an unaudited balance sheet. And let’s not forget this is a company with a very secretive history.

There are a few things that could be going on here (just to be clear, all we can do is speculate at this point). First of all, Valeant may have to incur some big asset impairments, especially now that its pricing practices are under such scrutiny. Even more worryingly, the company may be in breach of a financial covenant.

Mr. Pearson said he expects Valeant to be in compliance with all its financial covenants this year and next, but without audited financial statements, it’s difficult to say for sure.

What must be done

What’s become clear is that Valeant needs to sell assets to shore up its balance sheet. Yet there are serious doubts about whether or not this will be enough. One veteran healthcare analyst even told The New York Times that he’s not sure the businesses are worth more than the debt load.

Of course, if Valeant has to write down some assets, then selling them off may be even more challenging. And if the company needs to sell assets to comply with financial covenants, then this must be done before the 10K is filed. Again, this is very speculative, but it’s something you need to consider before buying shares of the company.

Put simply, this is a stock you should stay very far away from.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Energy Stocks

Why Shares of Cameco Are Powering Higher

Cameco (TSX:CCO) shares have surged more than 400% in the last five years alone, with more growth on the way.

Read more »

A bull outlined against a field
Stocks for Beginners

Bull Market Buys: 2 TSX Stocks to Own for the Long Run

Are you looking for stocks that could see a bull run for decades ahead? Here are two top TSX stocks…

Read more »

financial freedom sign
Dividend Stocks

Million-Dollar TFSA: 1 Way to Achieve to 7-Figure Wealth

Achieving seven-figure TFSA wealth is doable with two large-cap, high-yield dividend stocks.

Read more »

analyze data
Dividend Stocks

How Much Will Manulife Financial Pay in Dividends This Year?

Manulife stock's dividend should be safe and the stock appears to be fairly valued.

Read more »

food restaurants
Dividend Stocks

Better Stock to Buy Now: Tim Hortons or Starbucks?

Starbucks and Restaurant Brands International are two blue-chip dividend stocks that trade at a discount to consensus price targets.

Read more »

Diggers and trucks in a coal mine
Metals and Mining Stocks

1 Canadian Mining Stock Worth a Long-Term Investment

Cameco (TSX:CCO) stock could be a great long-term investment for Canadian growth seekers.

Read more »

Pot stocks are a riskier investment

Could Investing $10,000 in Aurora Cannabis Stock Make You a Millionaire?

Let's dive into whether Aurora Cannabis (TSX:ACB) could be a potential millionaire-maker stock, or a dud, over the long term.

Read more »

stock analysis
Energy Stocks

Is Enbridge Stock a Good Buy in May 2024?

Boasting high-yielding dividends and a stable underlying business, Enbridge (TSX:ENB) might be a great buy for your self-directed investment portfolio…

Read more »